There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Esperion (ESPR), Opko Health (OPK) and Capricor Therapeutics (CAPR) with bullish sentiments.
Esperion (ESPR)
Northland Securities analyst Carl Byrnes maintained a Buy rating on Esperion today and set a price target of $65. The company’s shares opened today at $38.04, close to its 52-week low of $36.06.
Byrnes commented:
“We remain highly optimistic that BA and its FDC combination will be approved on their respective PDUFA dates in late-February 2020. Further, we note that the Co. has bolstered its coffers with its recent $200MM revenue interest purchase agreement with Oberland Capital that added $125MM in 2Q19. Esperion reported 2Q results, with a lower- than-expected net loss of ($54.2MM), vs. our estimate of ($56.0MM). EPS tracked ($2.01) on lower shares outstanding of 27.0MM. RD spending totaled $42.8MM, slightly higher than our forecast of $40.0MM, which was offset by lower SG&A spending of $13.5MM, vs. our estimate of $16.0MM.”
According to TipRanks.com, Byrnes is ranked 0 out of 5 stars with an average return of -15.3% and a 16.2% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Aridis Pharmaceuticals Inc, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Esperion is a Moderate Buy with an average price target of $88.29.
See today’s analyst top recommended stocks >>
Opko Health (OPK)
In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health, with a price target of $4. The company’s shares opened today at $1.99, close to its 52-week low of $1.73.
Petusky noted:
“We continue to rate OPK shares an OUTPERFORM but are slightly lowering our price target to $4 (from $5 previously) given our reduced expectations for performance at BRL and our less optimistic outlook for the uptake of RAYALDEE over the next couple of years. We arrive at our price target via the use of DCF methodology. It is important to note that the company still has many “shots on goal” within both its current commercial portfolio as well as its product development pipeline. Company Description OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments.”
According to TipRanks.com, Petusky is a 3-star analyst with an average return of 2.5% and a 45.5% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
The word on The Street in general, suggests a Hold analyst consensus rating for Opko Health.
Capricor Therapeutics (CAPR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics, with a price target of $19.50. The company’s shares opened today at $3.48, close to its 52-week low of $2.53.
Pantginis wrote:
“Valuation and potential impediments to achieving it. We reiterate our Buy rating and are adjusting our price target to $19.50 from $12.40 based on: (1) accounting for the June 2019 1:10 reverse split; and (2) increasing our discount rate to 45% from our usual 15% to add a layer of conservatism based on awaiting FDA pivotal guidance visibility and ongoing financing needs of the company should the DMD program continue to move forward. We also highlight the current delta between the current share price and our price target, which is now also based the low share count post-reverse split.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -12.8% and a 28.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.
Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $19.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
